StreetAlpha.app
Home › Stocks › CRIS

Curis Inc (CRIS)

$0.43
▼ −9.03%
LAST CLOSE · NOV 20

Curis is a Lexington, Massachusetts biotechnology company developing emavusertib, an oral drug candidate for blood cancers. It last closed at $0.43 on Nov 20, down 9.03% on the day. The next earnings report for CRIS is expected around Thu, Mar 18, 2027, after the close. For the quarter ended Sep 2026, CRIS reported EPS of -$1.94. Over its last 8 reports the stock moved an average of 5.4% the session after earnings. Over the last 12 months CRIS insiders bought $5K of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is CRIS in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold CRIS.

Key Stats

Last 12 months
Results
Net income
−$21.5M
Valuation
Market cap
$4.1M
9.5M shares
P/E
–
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$5.0M
At Sep 30
Shareholder equity
$2.6M
Shares outstanding
9.5M
At Nov 10
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $10.6M$10.6MFY2021FY2022: $10.2M$10.2MFY2022FY2023: $10.0M$10.0MFY2023FY2024: $10.9M$10.9MFY2024FY2025: $9.4M$9.4MFY2025

From CRIS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.

Next report
Mar 18
Estimated date · After the close
Reported EPS
-$1.94
Quarter ended Sep 2026
Year ago EPS
-$9.86
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$1.11Dec '24Mar 2025: -$1.25Mar '25Jun 2025: -$13.61Jun '25Sep 2025: -$9.86Sep '25Dec 2025: $43.24Dec '25Mar 2026: -$1.25Mar '26Jun 2026: -$4.02Jun '26Sep 2026: -$1.94Sep '26Latest -$1.94
Revenue by quarter
Dec 2024: $3.3MDec '24Mar 2025: $2.4MMar '25Jun 2025: $2.7MJun '25Sep 2025: $3.2MSep '25Dec 2025: $1.1MDec '25Mar 2026: $0Mar '26Jun 2026: $0Jun '26Latest $0
How CRIS moved after its last 8 reports
Average move the session after a report ±5.4%
Nov 13, 2026After the close−2.1%
May 12, 2026After the close−9.2%
Mar 19, 2026After the close+1.9%
Nov 6, 2025After the close−10.3%
Aug 5, 2025Time not announced+4.4%
May 6, 2025Time not announced−10.6%
Mar 28, 2025Time not announced−3.7%
Nov 14, 2024Time not announced+1.3%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on CRISStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on CRIS
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on CRIS

Technical Analysis

CRIS · as of the Nov 20 close · updated each morning
Downtrend

The stock is 41% below its 20 day and 62% below its 50 day average. It is 1704% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 40). The nearest support is the swing low (Nov 16) at $0.42, and the nearest resistance the Pivot at $0.45.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityHigh, 38.7%/day
Key levels
$28.4052 week high+6504.7%
$7.71200 day average+1693.0%
$2.02100 day average+369.8%
$0.82Swing high (Oct 8)+90.7%
$0.6950 day average+60.5%
$0.6020 day average+39.5%
$0.47Pivot R1+9.3%
$0.45Pivot+4.7%
$0.43Last close
$0.42Swing low (Nov 16)−2.3%
$0.40Pivot S1−7.0%
$0.3352 week low−23.3%
Indicators
RSI (14)40.41Middle of its rangeNeutral
MACD-0.07Below its signal lineBearish
Stochastic7.4Near the bottom of its rangeOversold
ADX (14)30.0Trending up
Williams %R-99.1Oversold below −80, overbought above −20Oversold
CCI (20)-71.3Oversold below −100, overbought above 100Neutral
Rate of change−52.9%Change over 10 sessionsBearish
ATR (14)$0.17Typical daily range, 38.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CRIS

What happened before

See how CRIS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow CRIS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How CRIS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for CRISHow many large options trades hit CRIS, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

CRIS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼27 buying vs 39 selling
  • ▼Held by funds -128.8 pts
  • ▼Funds holding -11
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding2839−28.2%
In funds' top 10110.0%
Held by funds12.2%141.0%−128.8 pts
New / increased27 / 07 / 4+145.5%
Reduced / sold out1 / 3810 / 12+77.3%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CRIS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

CRIS Insider Trading

All filings →
Insider trading · 12 months
Insiders are buying
Bought$5K1 buy · 1 insider
Sold$00 sales · 0 insiders
2026-03 bought $5KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Mar 31Kenneth I KaitinDirectorBuy10,000$0.55$5K
Every insider buy and sale for CRIS over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See CRIS insider trades →

From SEC Form 4 filings by CRIS's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CRIS is in one of them and how their past CRIS trades turned out.

CRIS in the AI portfolios
Loading…

CRIS News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CRIS in an article yet. Here's the latest on the wider market.

CRIS in the news

About Curis

Curis is a biotechnology company based in Lexington, Massachusetts, that is developing emavusertib, an oral small molecule drug candidate for blood cancers. The drug is designed to block two cell signaling proteins, IRAK4 and FLT3, which help certain leukemias and lymphomas grow and survive. Curis is testing emavusertib in clinical studies for patients with relapsed or refractory primary central nervous system lymphoma and for patients with chronic lymphocytic leukemia, both in combination with other cancer drugs. The company does not yet have an approved product for sale, so its patients are those enrolled in its clinical trials.

Headquarters
Lexington, MA